Viatris reports Q3 2026 net loss of $325 million
Pharmaceutical company Viatris posted a $325 million net loss for the third quarter of 2026, even as total revenues reached $3.75 billion.
Viatris announced total revenues of $3.75 billion for the third quarter of 2026. Despite this revenue figure, the company reported a U.S. GAAP net loss of $325 million. Adjusted EBITDA for the period stood at $1.20 billion, providing a clearer view of operational performance excluding specific accounting charges.
Operational developments included regulatory approval for RYZUMVI for the treatment of presbyopia in the U.S. and WAKIX in Japan. These milestones are critical as Viatris continues to navigate a competitive pharmaceutical landscape, focusing on expanding its therapeutic reach in key international markets.
Year-to-date, Viatris has returned approximately $717 million to shareholders through capital distribution. The company's financial results reflect broader sector trends involving significant R&D costs and ongoing efforts to balance portfolio expansion with shareholder returns.